A recent research letter published in JAMA by Chetty et al describes the experience of a secret shopper in obtaining GLP-1 receptor agonists (GLP-1 RA) from online sources.
Letters from the Director Archive
PCOS was recently renamed polyendocrine metabolic ovarian syndrome (PMOS) to address the inadequate treatment that has resulted from its perception as a condition limited to fertility.
Lessons from the STOP Obesity Alliance: A Reflection on Obesity Advocacy
This month's author is, Aden Belay, MPH, the STOP Obesity Alliance student research assistant who recently graduated from the Milken Institute School of Public Health.
A Pathway to Coverage of GLP-1s in Medicare and Medicaid
Last fall, the Trump administration announced an historic expansion of obesity treatment coverage for Medicare and Medicaid beneficiaries.
Weight Regain After Obesity Treatment
As options for the treatment of obesity have rapidly expanded, a major concern has been weight regain among treated patients with obesity.
Obesity Care Week (OCW) brings together advocates and organizations nationwide to raise awareness, educate, and advocate for people affected by obesity.
The New Dietary Guidelines for Americans, 2025-2030
Earlier this month, the US Department of Health and Human Services (HHS) and the US Department of Agriculture (USDA) released the 2025-2030 Dietary Guidelines for Americans (DGAs).
Guest Letter: A Path Forward: What’s Possible for Obesity Care in 2026
Last month, the administration delivered another critical victory: a landmark Medicare and Medicaid price negotiation deal for the GLP-1 medications Wegovy and Zepbound.
Inclusive and supportive workplaces for people with obesity remain the exception rather than the norm.
The Changing Global Obesity Landscape
The global burden of obesity continues to rise. Without effective and collective action, overweight and obesity will continue to increase globally.